A

    Arcturus Therapeutics Holdings Inc (ARCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.76
    -0.43 (-2.83%)

    Market Cap: $431.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +2.68%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.67
    Range$-0.92 - $-0.29
    10 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.88-30.5%
    60d ago$-0.88-30.5%
    30d ago$-0.88-31.0%
    7d ago$-0.67+0.0%
    Current$-0.67
    Revenue Consensus
    $8M
    Range$2M - $16M
    13 analysts
    Dec 31, 2026
    EPS Consensus$-0.58
    Range$-1.12 - $-0.01
    9 analysts
    Revenue Consensus
    $603630
    Range$-9703750 - $15M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.58---
    Sep 26EST
    		-$-0.67---
    Jun 26
    		$-0.84$-1.07+21.50%Beat-147.1%
    Mar 26
    		$-0.95$-1.01+6.25%Beat-82.7%
    Dec 25
    		$-1.03$-0.76-35.53%Miss+7.2%
    Sep 25
    		$-0.49$-0.80+38.75%Beat-88.5%
    Jun 25
    		$-0.34N/A+60.00%Beat+46.9%
    Mar 25
    		$-0.52N/A+52.73%Beat+48.0%
    Dec 24
    		$-1.11$-0.49-124.56%Miss-246.9%
    Sep 24
    		$-0.26N/A+74.51%Beat+57.4%
    Jun 24
    		$-0.64N/A+59.24%Beat+67.7%
    Mar 24
    		$-1.00$-1.14+12.28%Beat-258.7%
    Dec 23
    		$-0.32N/A+67.68%Beat-107.2%
    Sep 23
    		$-0.61N/A+62.58%Beat+54.1%
    Jun 23
    		$-1.98$-0.42-371.43%Miss-141.5%
    Mar 23
    		$0.63$0.26+142.31%Beat+132.5%
    Dec 22
    		$4.43$0.98+352.04%Beat+401.4%
    Sep 22
    		$-1.33$-1.81+26.52%Beat+35.1%
    Jun 22
    		$-0.82N/A+56.38%Beat+60.4%
    Mar 22
    		$-1.94$-1.40-38.57%Miss+9.8%
    Dec 21
    		$-1.47$-1.72+14.53%Beat-17.6%
    Sep 21
    		$-2.05$-1.52-34.87%Miss-122.8%
    Jun 21
    		$-2.07$-2.25+8.00%Beat-276.4%
    Mar 21
    		$-2.15$-1.23-74.80%Miss-220.9%
    Dec 20
    		$-1.25$-0.88-42.05%Miss-64.5%
    Sep 20
    		$-0.92$-0.49-87.76%Miss-64.3%
    Jun 20
    		$-0.55$-0.55+0.00%Beat-685.7%
    Mar 20
    		$-0.67$-0.61-9.84%Miss+1.5%
    Dec 19
    		$-0.76$-0.51-49.02%Miss-850.0%
    Sep 19
    		$-0.56$-0.46-21.74%Miss-33.3%
    Jun 19
    		$-0.07N/A+88.52%Beat+92.9%
    Mar 19
    		$-0.68$-0.60-13.33%Miss+37.0%
    Dec 18
    		$-0.08N/A+83.33%Beat+92.6%
    Sep 18
    		$-0.42$-0.35-20.00%Miss+40.0%
    Jun 18
    		$-0.99$-0.70-41.43%Miss-8.8%
    Mar 18
    		$-1.08$-0.46-134.78%Miss-18.7%
    Dec 17
    		$-1.08$-0.46-134.78%Miss+29.9%
    Sep 17
    		$-0.70N/A+73.68%Beat+64.3%
    Jun 17
    		$-0.91$-0.94+3.19%Beat-
    Mar 17
    		$-0.91$-1.26+27.78%Beat-
    Dec 16
    		$-1.54$-1.90+18.95%Beat-
    Sep 16
    		$-1.96$-1.80-8.89%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.46EV/EBITDA-25.67x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-863.00%
    ROE-46.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio5.88xQuick Ratio5.88x
    Trading Statistics
    Beta2.27Avg Volume1.39M
    52-Week High$24.1752-Week Low$5.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.47
    SMA 20$10.35
    SMA 50$8.04
    SMA 200$7.59
    EMA 10$13.54
    EMA 20$11.45
    EMA 50$9.16
    EMA 200$8.89

    MACD

    Line: 2.36Signal: 1.75Hist: 0.61

    ADX

    ADX: 56.3+DI: 39.8-DI: 9.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$16.59

    Bollinger Bands

    Upper Band$17.83
    Lower Band$2.87
    %B Position14456%(Upper)
    Band Width0.79

    RSI (14-Day)

    Overbought
    77.5

    Momentum Oscillators

    Stoch %K87.0
    Stoch %D90.7
    Williams %R-20.1
    ROC (10d)81.3%
    Momentum6.62
    CCI (20d)94.9
    MFI (14d)84.6

    Volatility Measures

    ATR (14d)$1.14(7.7%)
    StdDev (20d)3.74
    Hist Vol139.2%(High)

    Volume Flow

    VWAP$14.86
    OBV1.7M
    AD Line4.1M
    CMF (20d)0.302

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.9x
    VWMA (20d)$11.78

    Pivot Points

    R3$17.31
    R2$16.60
    R1$15.90
    Pivot Point$15.19
    S1$14.49
    S2$13.78
    S3$13.08

    Advanced Oscillators

    TSI68.41
    Ultimate Osc67.9
    KST1010.60

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.96M$2.06M$7.20M$17.15M$28.30M$29.38M$22.77M$41.67M$49.86M$38.01M$30.86M$45.14M
    Cost of Revenue$0$0$682,000$0$0$0$819,000$0$0$0$815,000$0
    Gross Profit$2.96M$2.06M$7.20M$17.15M$28.30M$29.38M$22.77M$41.67M$49.86M$38.01M$30.86M$45.14M
    Operating Expenses$28.50M$30.99M$38.50M$33.66M$39.92M$46.21M$56.16M$52.41M$70.98M$68.42M$49.13M$64.45M
    R&D$17.52M$21.53M$24.48M$23.27M$29.58M$34.89M$43.78M$39.13M$58.67M$53.57M$36.62M$51.08M
    SG&A$10.99M$9.46M$14.03M$10.40M$10.34M$11.31M$12.38M$13.28M$12.32M$14.85M$12.51M$13.38M
    Operating Income$-25,545,000$-28,931,000$-31,306,000$-16,512,000$-11,616,000$-16,826,000$-33,394,000$-10,737,000$-21,126,000$-30,412,000$-18,272,000$-19,314,000
    Interest Income$1.82M$1.93M$0$0$2.57M$2.77M$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-23,785,000$-26,964,000$-29,083,000$-13,448,000$-9,176,000$-14,076,000$-30,010,000$-7,120,000$-17,366,000$-26,449,000$-11,445,000$-15,329,000
    Income Tax Expense$0$0$-4,000$0$4,000$0$-5,000$-217,000$-150,000$368,000$262,000$893,000
    Net Income$-23,785,000$-26,964,000$-29,079,000$-13,448,000$-9,180,000$-14,076,000$-30,005,000$-6,903,000$-17,216,000$-26,817,000$-11,707,000$-16,222,000
    EBITDA$-24,961,000$-28,238,000$-28,401,000$-12,685,000$-10,964,000$-16,046,000$-29,191,000$-6,208,000$-16,457,000$-25,545,000$-10,630,000$-14,502,000
    EBIT$-25,604,000$-28,896,000$-29,083,000$-13,448,000$-11,743,000$-16,847,000$-30,010,000$-7,120,000$-17,366,000$-26,449,000$-11,445,000$-15,329,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARCT

    News

    Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ

    Arcturus Therapeutics Holdings Inc. (ARCT) saw a significant price increase of 23.12%, adding $2.54 to its stock value. The article provides live quotes and charts for ARCT but notes that there is no current analyst rating data or earnings information available for the company. It also includes disclaimers about investment risks and the informational nature of the content.

    StocksToTrade•8/22/26•
    Bullish

    ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows

    Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the company's strong balance sheet and advancing Phase 2 trials for ARCT-032 and ARCT-810 are providing catalysts for traders. Analysts maintain a "Buy" rating, seeing the recent collaboration changes and cash injection as beneficial for the company's future.

    StocksToTrade•8/19/26•
    Bullish

    Liquidity Mapping Around (ARCT) Price Events

    This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for ARCT.

    Stock Traders Daily•8/16/26•
    Somewhat-Bearish

    We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

    This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial health and potential need for future funding.

    Moomoo•8/14/26•
    Somewhat-Bearish

    Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

    Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase III in the fourth quarter, based on ongoing Phase II data. Additionally, Arcturus anticipates reporting data and regulatory updates for its injectable mRNA therapy for OTC deficiency (ARCT-810) before September 30, while maintaining a cash runway through 2028.

    TradingView•8/12/26•
    Bullish

    Frequently Asked Questions About ARCT

    Does ARCT pay dividends?
    Arcturus Therapeutics Holdings Inc (ARCT) does not currently pay a regular dividend.
    What is ARCT's market cap?
    Arcturus Therapeutics Holdings Inc (ARCT) has a market capitalization of $431.75M with a current stock price of $14.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In